Loading...

Home
Stock
ARGX

ARGX News & Events

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Stock Price Prediction Technical Valuation Financials Earnings Should I Buy News & Events

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

ARGX News

argenx Hosts Webinar on Advancing FcRn Leadership in Autoimmune Myositis

4d agoNewsfilter

argenx Management to Attend Investor Conferences in June

5d agoNewsfilter

MindWalk Reports Significant Progress in Drug Development

May 18 2026Newsfilter

argenx SE Receives FDA Approval for VYVGART Label Expansion

May 11 2026NASDAQ.COM

FDA Approves Label Expansion for Vyvgart in Myasthenia Gravis

May 09 2026seekingalpha

FDA Approves VYVGART for All Adult gMG Patients

May 08 2026Newsfilter

argenx SE Q1 Earnings Beat Expectations

May 07 2026seekingalpha

argenx CEO to Present at BofA Healthcare Conference

May 06 2026Newsfilter

ARGX Events

No data

No data

ARGX Monitor News

argenx Receives FDA Approval for VYVGART Label Expansion

argenx SE hits 20-day low amid market decline

argenx SE Reports Positive Phase 3 Results for VYVGART in Ocular Myasthenia Gravis

argenx SE Reports Strong Q4 Results Amid Market Weakness

argenx Reports Strong Q4 Earnings and Future Growth Plans

argenx SE reaches 20-day high amid market gains

argenx SE transitions leadership amid market strength

argenx discontinues Phase 3 TED studies, shares decline

ARGX Earnings Analysis

Argenx SE Earnings: Immunology Innovations Drive Growth- Intellectia AI™

argenx SE 2024: Earnings Growth & Strategic Advancements- Intellectia AI™

People Also Watch